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Summary Reserpine was found to enhance the cytotoxicity of ACNU on ACNU-resistant C6 glioma
(C6/ACNU) cells in vitro. When reserpine was added along with ACNU to the C6/ACNU cells in vitro. When
reserpine was added along with ACNU to the C6/ACNU culture in vitro at a concentration of 10JM, the
IC50 of ACNU for C6/ACNU cells decreased to the level of that for C6 cells and ACNU resistance was
completely overcome in vitro. Furthermore, intracellular uptake of ACNU increased in both sensitive (C6) and
resistant (C6/ACNU) glioma cells when 2OJM reserpine was added to the culture medium. Reserpine (20 M)
enhanced the cellular level of ACNU in C6 cells 1.5-fold and enhanced the level of ACNU in C6/ACNU cells
4-fold. The amount of ACNU incorporated into C6/ACNU cells reached the same level as that incorporated
into C6 cells. The enhanced cytotoxicity of ACNU in vitro could be explained by the effective intracellular
accumulation of ACNU resulting from the increase of intracellular uptake of ACNU in C6/ACNU cells by
reserpine.
One of the most serious problems in the chemo-
therapy of malignant tumours is that tumour cells
are rapidly able to acquire resistance to initially
effective chemotherapeutic agents (Salmon et al.,
1978). A nitrosourea derivative 1-(4-amino-2-
methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-
nitrosourea hydrochloride (ACNU), is sometimes
used with other nitrosourea derivatives in the
chemotherapy of brain tumours and shows con-
siderable efficacy, because it easily crosses the
blood-brain barrier (BBB) (Shimizu et al., 1980;
Ushio et al., 1981). Recently, however, the
emergence of variant cells resistant to ACNU has
become a controversial issue in brain tumour
chemotherapy (Aida et al., 1985; Kokunai et al.,
1985; Yoshida et al., 1984). In spite of the
importance of resistance in the chemotherapy of
brain tumours, research in this field is limited.
Apart from our report (Yoshida et al., 1984), there
is little information in the literature regarding drug
resistance in malignant brain tumours (Aida et al.,
1985; Kokunai et al., 1985; Merry et al., 1984).
In order to investigate the mechanism of
resistance to ACNU in brain tumours and the
possibility of overcoming ACNU resistance, we
have selected, in vivo, a variant subline resistant to
ACNU from rat C6 glioma cells. We have also
studied the intracellular uptake of ACNU in
ACNU-resistant C6 glioma (C6/ACNU) cells.
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Furthermore, after examining the effects of a
number ofmembrane-modifying agents on the cyto-
toxicity and the cellular uptake of ACNU in
C6/ACNU cells, reserpine, at a nontoxic dose, was
found to enhance the cytotoxicity of ACNU and to
increase the intracellular uptake of ACNU in
C6/ACNU cells. ACNU resistance in C6/ACNU
glioma cells has been completely overcome by
reserpine in vitro.
Materials and methods
Tumours and animals
Male Wistar rats weighing 100g were used in
experiments. A subline of C6 glioma resistant to
ACNU (C6/ACNU) was developed by treating
Wistar rats in which 1 x 107 of C6 glioma cells were
transplanted percutaneously into the cisterna
magna with ACNU (1 mgkg 1, intrathecally, i.t.)
over successive transplant generations, as previously
described (Yoshida et al., 1984). Complete
resistance in vivo to maximally tolerated doses of
ACNU was evident after a 2nd transplant
generation of exposure to the drug. After 5
generations of drug exposure, the ACNU-resistant
line was split into two sublines; one was maintained
in drug-treated rats and the other was transplanted
without further drug treatment. Resistance proved
to be stable for at least 50 transplant generations in
the absence of the drug. Resistant cells used in the
present study were from a subline which was
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maintained in ACNU treated animals. However,
treatment with ACNU was discontinued one trans-
plant generation prior to the harvest of cells used in
experiments described herein. The resistant tumour
was transferred to in vitro culture after being
minced in saline solution and dispersed with 0.25%
trypsin at 37°C for 20min. Both C6 and C6/ACNU
cells were cultured in Falcon No. 3024 culture
bottle (Falcon Plastics, Oxnard, CA, USA) in
Eagle's MEM (Grand Island Biological Co., Grand
Island, NY, USA) supplemented with 10% heat-
inactivated foetal bovine serum (Grand Island
Biological Co.), 10 pM 2-mercaptoethanol (Sigma
Chemical Co., St. Louis, Mo., USA), penicillin base
(50Uml-1), and streptomycin base (50pgml-1)
(both from Grand Island Biological Co.). Stock
cultures were incubated at 37°C in a humidified
atmosphere supplied with 5% CO2. The cells were
subcultured twice and then used for experiments.
As a rule, the cells were kept continuously in the
culture for <3 weeks, and there was essentially no
change in drug sensitivity and ACNU resistance
during that period.
Drugs
ACNU formulated for clinical use and [14C]ACNU
(5.25mCimmol-1) were obtained from Sankyo
Pharmaceutical Co., Ltd. (Tokyo, Japan), and
reserpine was kindly supplied by Daiichi Pharma-
ceutical Co., Ltd. (Tokyo, Japan).
Cytotoxicity assay
Culture medium (1 ml) containing 1 x 104 C6 and
C6/ACNU cellsml-1 of the medium was trans-
ferred to Falcon No. 3047 plates. Three wells were
used for each drug concentration. The cells were
incubated at 37°C in a humidified atmosphere of
5% CO2. Twenty-four hours later, ACNU and
reserpine dissolved in PBS were added successively
to the culture. After cultivating further for another
96h, viable cells were enumerated by trypan blue
exclusion. The cytotoxic activity of ACNU in the
absence or presence of reserpine was measured by
determining the IC50 (concentration of drug
required for 50% inhibition of cell growth) which
was obtained by plotting the logarithm of the drug
concentration vs. the growth rate (percentage of
control) of the treated cells.
Cellular uptake of[14C]ACNU
Culture medium (1 ml) containing 5 x 105 C6 and
C6/ACNU cellsml -1 of medium was transferred
to Falcon No. 3047 plates and incubated at
37°C for 24h. Three wells were used for each
drug. [14C]ACNU (lOpgml-; specific activity,
5.25mCimmol-1) was added to each well and
incubated further with or without reserpine (20pM).
At various time intervals, the culture medium was
discarded and the cells were washed 3 times with
1 ml of cold PBS. The cells were lysed overnight
with 400 1 of I N NaOH and 60Oul of 9NHCI was
added in the wells. The lysates were transferred to
scintillation vials containing 7ml of scintillator
(Univer Gel-2, Nakarai Chemical Co., Kyoto,
Japan), and the radioactivity was counted in a
liquid scintillation spectrometer (Mark 3, 6881
Liquid Scintillation System, Tracor Analytic). The
amount of drug incorporated into the cells was
expressed as pmol 10-I cells.
Results
Enhanced cytotoxicity of ACNU in C6 and
C6/ACNU cells by reserpine
The sensitivities of C6 and C6/ACNU cells to
ACNU and the effect of reserpine on the sensitivity
are illustrated in Figure 1 and Table I. C6/ACNU
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Figure 1 Effect of reserpine upon growth-inhibitory
action of ACNU on C6/ACNU cells. C6 cells were
incubated with ACNU at the indicated concentrations
in the absence (*-*) of reserpine, and C6/ACNU
cells were treated with ACNU at the indicated
concentrations in the absence (0-0) or presence of
lOpM reserpine (O---0). Each point is the mean of 3
determinations (s.d. + 10%).
Table I Enhanced effect of reserpine upon
growth-inhibitory action of ACNU on
ACNU-resistant C6 glioma
IC50 ofACNU
(Lgml- ±s.d.)
Modifier (Mm) C6 C6/ACNU
Control 8.3+1.3 120+1.5
Reserpine 10 4.1 +0.9a 8.0+0.4b
20 3.1+0.7a 2.5+0.5b
ap<0.05; bp<0.001 by Student t test.EFFECT OF RESERPINE ON ACTION OF ACNU
cells showed high resistance to ACNU, and the
IC50's of ACNU for C6 and C6/ACNU cells were
-8.3 and 120pgml-1, respectively. Reserpine at a
nontoxic dose of 10IM greatly enhanced the cyto-
toxicity of ACNU for C6/ACNU cells. When
reserpine was added along with ACNU to
C6/ACNU cell cultures at a final concentration of
10/M, IC50 of ACNU shifted from 120 to
8.0 4ugml-'. This value was almost the same as the
IC50 (8.3pgml-1) of ACNU for C6 cells in the
absence of reserpine. Both C6 and C6/ACNU cells
showed the same sensitivity to reserpine. At
reserpine concentrations up to 40pM, no growth
inhibition was observed for either cells.
Cellular uptake ofACNU and the effect of reserpine
Cellular uptake of [14C]ACNU by C6 and
C6/ACNU cells in the absence or presence of
reserpine is presented in Figure 2. The uptake of
[14C]ACNU into cultured C6 cells increased with
time under conditions of constant drug exposure.
Approximately 3.4pmol of ACNU was found at 5h
in 105 C6 cells, while the amount of ACNU in
C6/ACNU cells was much smaller and the level
almost reached a plateau (0.8pmol 105 cells) 1 h
after incubation. There was a 4-fold difference in
the incorporation between the 2 cell lines by 5h.
Reserpine added to the culture at 20 M greatly
increased the amount of cellular ACNU in both C6
and C6/ACNU cells. The Amounts of ACNU
found in C6 and C6/ACNU cells treated with
reserpine were 4.3 and 3.0pmol 10-5 cells,
respectively. Almost a 4-fold accumulation of
ACNU occurred in reserpine-treated C6/ACNU
cells during 4-5h of incubation, while only 1.5-fold
the amount of ACNU was detected in C6 cells
treated with reserpine. The enhanced cytotoxicity of
ACNU in C6/ACNU cells by reserpine in vitro
could be explained by this phenomenon.
Discussion
The development of variant cell lines that are
resistant to chemotherapeutic drugs, including
ACNU, is a frequent complication in chemo-
therapy (Salmon et al., 1978; Yoshida et al., 1984).
Although many investigators have studied drug
resistance in various tumour cell lines, there are
only a few reports of drug resistance in brain
tumours (Aida et al., 1985; Kokunai et al., 1985;
Merry et al., 1984). We have previously isolated
and propagated in vivo a variant cell line of rat C6
glioma that is highly resistant to the cytotoxic
action of ACNU (Yoshida et al., 1984). In the
induction of ACNU resistance in vivo, emphasis
was placed on the development of resistance in the
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Figure 2 Effects of reserpine on the uptake of
[14CJACNU by C6 and C6/ACNU cells. C6 cells were
incubated with 10 gmlml [14C]ACNU in the absence
(*-*) or presence of reserpine at 20M (O-O).
C6/ACNU cells were also incubated with 10 gml-l
[14C]ACNU in the absence (0-0) or presence of
reserpine at 20 M (0 0). Each point is the mean of
3 determinations (s.d. . +10%).
course of therapy with ACNU as the selection of
resistant cells in this manner is thought to be more
realistic. In the present study, the cellular concen-
trations of ACNU in C6/ACNU cells were almost 4
times lower than those found in C6 cells. Reserpine
has enhanced the cytotoxicity of ACNU in
C6/ACNU cells, and could completely overcome
ACNU resistance in vitro. At a nontoxic dose of
20gM of reserpine, the cellular level of ACNU in
C6/ACNU cells increased to almost the same extent
as that in C6 cells (Figure 2). Actually, in in vitro
experiments, the sensitivities of C6 and C6/ACNU
cells to ACNU were almost equal when 1O0M
reserpine was added along with ACNU to the
culture (Figure 1, Table I).
While examining a number of membrane inter-
acting agents, it was found that reserpine enhances
the cytotoxicity of ACNU in ACNU-resistant
glioma cells and increases the intracellular uptake
of ACNU in the cells. The mechanism of enhance-
ment of the cytotoxicity of ACNU in C6/ACNU
cells by reserpine is not known. However, Koshiura
et al. (1980) discovered the enhanced effect of the
chemotherapeutic agent 1-(gamma-chloropropyl)-2-
chloromethylpyrimidine hydrochloride (CAP-2), in
AH-13 and AH-44 cells by reserpine and reported
the mechanism to be inhibition of DNA repair.
Contrary to this report, we showed an increase of
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cellular uptake of ACNU in both C6 and
C6/ACNU cells treated with reserpine. It is
suggested that the enhanced effect of the cyto-
toxicity of ACNU in C6/ACNU cells is due to the
increase of intracellular ACNU. This is supported
by Inaba et al. (1981) to the effect that reserpine
circumvented resistance to adriamycin and vin-
cristine in P388 leukaemia cells. As for the actions
of reserpine, antitumour activity against hypoxic
cells was also reported (Lehnert, 1982), but the
precise mechanism of this activity has not been
clarified. On the other hand, it has been disclosed
that reserpine decreases the amount of calcium in
the heart, blood vessels and brain (Carrier et al.,
1970; Ross et al., 1974), and that calcium bound to
lipid of cell membranes is released by reserpine
(Wang & Radouco-Thomas, 1978). Recently,
Tsuruo et al. (1983) reported that the mechanism of
drug resistance is due to both the reduced uptake
of the drug and the increased active efflux of the
intracellular drug from the resistant cells showing
the intracellular accumulation of the drug by
calcium antagonists. They have stressed that the
mechanism of drug resistance is profoundly related
to cell membrane calcium metabolism and cal-
modulin. The results of the present experiment are
consistent with their observation of reduced cellular
uptake of the drug in the resistant cells. Further-
more, the enhanced cytotoxicity of ACNU by
reserpine could be explained by their hypothesis, if
reserpine acts on the membrane as a calcium
antagonist as reported previously. However, the
data in the present study indicated an almost 50-
fold reduction in the IC50 (for 20pM reserpine) in
association with a four-fold increase in drug
uptake. Although the enhanced effect of the cyto-
toxicity of ACNU could be partially explained by
the increased cellular drug level, it is conceivable
that other mechanisms also apply. Kokunai et al.
(1985) reported that ACNU resistance in 9L glioma
is due to the increased DNA repair. Aida et al.
(1985) also referred to the increase of DNA repair
in an ACNU-resistant human glioma cell line (HU-
188) in which the activity of 06-methyl guanine
(06-mGua) DNA methyltransferase was high, and
they reported that the increased activity of this
enzyme is one of the causes of ACNU resistance in
HU-188 human glioma. On these considerations,
drug resistance is multifactorial and involves
calcium, the enzymes related to calcium metabolism
and cyclic AMP of the cell membranes (Inaba et
al., 1981) and DNA repair (Aida et al., 1985;
Kokunai et al., 1985). Although the enhanced effect
of the cytotoxicity of ACNU by reserpine presented
herein might also be related to these factors, it has
been shown that the mechanism of the enhanced
effect of reserpine is partially due to the increase of
the cellular accumulation of ACNU. The
mechanism of ACNU resistance has not been
elucidated. However, it seems that it is closely
related to reduced uptake of ACNU as advocated
in the present study. In order to investigate further
the mechanism involved in ACNU resistance in
C6/ACNU glioma, drug efflux in relation to
reserpine should be measured.
It might be very difficult to explain the
mechanism of drug resistance by a single
mechanism as it is generally considered that the
cause of drug resistance differs depending on the
type of tumour and the drug. However, we are
currently attempting to overcome ACNU resistance
in rat brain tumour models using the same cell lines
as those used in the present experiment. Moreover,
we are investigating the exact basis of ACNU
resistance by drug uptake and efflux studies in
ACNU-resistant glioma cell lines.
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